Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial

The Lancet 2026

View at publisher
Authors: Pablo Mora, Vanita R. Aroda, Marisse Asong, Matthias Blüher, Line Dam Heftdal, Amanda‐Louise Fenger Carlander, Louise Nygaard Vilsen, Julio Rosenstock
DOI: 10.1016/s0140-6736(26)01248-1
Cited by: 1
References: 26

Fields of Study & Subjects

Diabetes Treatment and Management Diabetes Cardiovascular Risks and Lipoproteins Regulation of Appetite and Obesity

Publication details

Journal / source
The Lancet
Publisher
Elsevier BV
Volume
408
Issue
10555
Pages
621–635
Publication date
30 July 2026
Language
EN